Age-specific effectiveness following each dose of acellular pertussis vaccine among infants and children in New Zealand  by Radke, Sarah et al.
Vaccine 35 (2017) 177–183Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vacc ineAge-specific effectiveness following each dose of acellular pertussis
vaccine among infants and children in New Zealandhttp://dx.doi.org/10.1016/j.vaccine.2016.11.004
0264-410X/ 2016 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author at: Conectus, UniServices, University of Auckland, Private
Bag 92019, Victoria St West, Auckland, New Zealand.
E-mail address: s.radke@auckland.ac.nz (S. Radke).Sarah Radke MSPH, PhD a,b,⇑, Helen Petousis-Harris BSc, PhD a, Donna Watson MAa,b, Dudley Gentles MSc b,
Nikki Turner MBChB, MPH, MD a
aDepartment of General Practice and Primary Health Care, University of Auckland, New Zealand
bConectus, UniServices, University of Auckland, New Zealand
a r t i c l e i n f oArticle history:
Received 5 August 2016
Received in revised form 17 October 2016
Accepted 1 November 2016
Available online 18 November 2016
Keywords:
Pertussis
Vaccine
Effectiveness
Waning
Immunizationa b s t r a c t
Background: Though it is believed the switch from whole cell to acellular pertussis vaccine has con-
tributed to the resurgence of pertussis disease, few studies have evaluated vaccine effectiveness (VE)
and duration of protection provided by an acellular vaccine schedule including three primary doses
but no toddler-age dose. We assessed this schedule in New Zealand (NZ), a setting with historically high
rates of pertussis disease, and low but recently improved immunisation coverage. We further evaluated
protection following the preschool-age booster dose.
Methods: We performed a nested case-control study using national-level healthcare data. Hospitalised
and non-hospitalised pertussis was detected among children 6 weeks to 7 years of age between
January 2006 and December 2013. The NZ National Immunisation Register provided vaccination status
for cases and controls. Conditional logistic regression was used to calculate dose-specific VE with dura-
tion of immunity examined by stratifying VE into ages aligned with the immunisation schedule.
Results: VE against pertussis hospitalisation was 93% (95% confidence interval [CI]: 87, 96) following
three doses among infants aged 5–11 months who received three compared to zero doses. This protection
was sustained through children’s fourth birthdays (VEP 91%). VE against non-hospitalised pertussis was
also sustained after three doses, from 86% (95% CI: 80, 90) among 5–11 month olds to 84% (95% CI: 80, 88)
among 3-year-olds. Following the first booster dose at 4 years of age, the protective VE of 93% (95% CI: 90,
95) among 4-year-olds continued through 7 years of age (VEP 91%).
Conclusions: We found a high level of protection with no reduction in VE following both the primary
course and the first booster dose. These findings support a 3-dose primary course of acellular vaccine
with no booster dose until 4 years of age.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Vaccination has made a substantial impact on the pertussis bur-
den; however, there is still significant morbidity and infant mortal-
ity worldwide. Many countries that shifted from the more
reactogenic whole cell to acellular pertussis vaccine have seen a
resurgence of pertussis disease [1], a phenomenon also observed
in countries still using the whole cell vaccines [2]. A range of expla-
nations have been offered, including lower initial efficacy and more
rapid waning for acellular vaccines. A lack of effect on carriage and
transmission is also likely to play a major role [2,3].Questions around acellular vaccine and pertussis re-emergence
have prompted recent examination of the duration of protection
that various schedules for acellular vaccines provide [4–22]. Most
studies are based on schedules with a second year of life booster
dose. Findings are mixed for the few studies based on schedules
with three primary doses and no toddler-age dose. The majority
of these studies showed sustained vaccine effectiveness (VE) up
to age 3 years [8,10,21,22]. Conversely, an Australian study that
demonstrated waning protection, from 79% in 1-year-olds to 59%
in 3-year-olds [9], motivated the re-instatement of a toddler-age
dose 11 years after it was discontinued from the Australian sched-
ule. No previous studies based on schedules without a toddler-age
dose have followed children past the age of 4 years.
Unlike other settings without a toddler dose, New Zealand (NZ)
has historically high rates of pertussis disease [23,24], and low but
recently improved immunisation coverage [25–27]. Acellular vac-
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15-month-old dose was discontinued, the immunisation schedule
has remained a primary diphtheria-tetanus-acellular pertussis
(DTaP) course recommended at 6 weeks, 3 months and 5 months
of age followed by a DTaP booster at 4 years and a reduced antigen
diphtheria–tetanus–acellular pertussis vaccine (Tdap) booster at
age 11 years [23].
To inform decision makers about the effectiveness of this sched-
ule, we assessed the duration of protection following the current 3-
dose primary series by measuring age-dose-specific VE against
hospitalised and notified pertussis. We similarly assessed the dura-
tion of protection following the 4-year-old booster dose, through to
children’s eighth birthdays.2. Methods
The vaccine used throughout this study period was Infanrix
hexa, a combined diphtheria-tetanus-acellular pertussis, hepatitis
B, enhanced inactivated polio vaccine and Haemophilus influenzae
type b vaccine.
Vaccination data were obtained from the National Immunisa-
tion Register (NIR). Routine NIR enrolment began with children
born in 2005 and has continued for subsequent birth cohorts. Par-
ents can opt to have some or all of their child’s information
excluded from the register. The cohort of children born January
1, 2006 through December 31, 2013 who were enrolled and never
had information opted-off the NIR formed the eligible study popu-
lation. The study cohort was followed for pertussis from birth to
December 31, 2013.
To report on hospitalisations and notifications separately, two
sources of data were used to detect pertussis disease: the National
Minimum Data Set (NMDS), a collection of administrative and clin-
ical information about all publicly funded hospitalisations; and
EpiSurv, NZ’s passive surveillance notifiable disease database.
Healthcare providers are required by law to report all clinically
suspect pertussis to public health [28]. Automatic electronic
reporting of positive specimens from laboratories has also been
required since 2007. Hospitalised pertussis cases were selected
from NMDS records with an International Classification of Dis-
eases, Tenth Revision, Australian Modification (ICD-10-AM) dis-
charge diagnosis code of A37 (A37.0–A37.9) in the primary or
any of the 99 available secondary diagnosis fields. Non-
hospitalised notified cases were sourced from EpiSurv records,
restricted to individuals who had no hospitalisation record for
the same episode of pertussis in the NMDS. Where an individual
child had multiple hospitalisations and/or notifications, only the
first was considered.
The NIR and two disease data sets were linked using National
Health Index (NHI) numbers, unique person identifiers assigned
at birth or at first healthcare contact for those born outside the
country. Cases with missing NHI numbers and any children with
inexplicable vaccination records (e.g., a child with vaccination date
prior to birth date) were excluded.
Dose-specific immunisation coverage was measured using per-
tussis immunisation event information for the children in the eligi-
ble NIR cohort. Age specific pertussis rates were calculated using
population estimates from the census. VE was estimated using a
nested case-control design.
Controls were children randomly selected via incidence density
sampling from the eligible NIR cohort. To maximise precision, 20
controls were selected per case, matched on date of birth and area
of residence. The age matching requirement was relaxed progres-
sively by day, either side of the case birthdate, until 20 controls
were selected. Controls were assigned an index date equal to thepertussis date (admission date for hospitalisations or report date
for notifications) for their matched case.
The exposure of interest was the number of pertussis vaccine
doses received prior to the pertussis date (cases) or index date
(controls). A wash-out period was applied, with a dose considered
received if it was administered at least 14 days prior to the pertus-
sis/index date.
Demographic characteristics were compared between cases and
controls using Pearson’s chi-square test. We used conditional logis-
tic regression to estimate odds ratios (OR). VE, as a percentage, and
associated 95% confidence intervals (CIs) were estimated using the
formula VE = (1  OR)  100. Separate models were fit with per-
tussis hospitalisations and non-hospitalised notifications as the
dependent variable and number of pertussis vaccine doses as the
independent variable. Duration of immunity was examined by
stratifying VE into ages aligned with the immunisation schedule
(age 6 weeks–2 months for dose 1; age 3–4 months for dose 2;
age 5–11 months, 1, 2 and 3 years for dose 3; and age 4, 5, 6 and
7 years for dose 4). Potential confounders (sex, ethnicity and
socioeconomic status based on the NZ Deprivation Index [29])
were included in models if they changed the vaccine-outcome
measure by at least 10% or if inclusion did not affect precision of
the VE estimate.
We performed multiple sensitivity analyses to check the
robustness of our findings. For hospitalisations and non-
hospitalised notifications we first restricted cases to those with
laboratory confirmation, either by isolation or PCR DNA detection
of B. pertussis, to examine possible misclassification bias. Sepa-
rately, we then examined our choice of a 14-day wash-out period
by reducing it to 7 days and again to 0 days, then stratified VE esti-
mates by birth year to assess the impact of recently improved vac-
cination coverage and timeliness. For case-control studies to
produce unbiased results, controls need to be selected from the
same population that gives rise to cases. For non-hospitalised noti-
fications in our study, this source population is made up of the
individuals who, had they become ill, would have sought health-
care and been notified. To account for variability in healthcare
seeking behaviour and practitioner reporting inherent in passive
surveillance systems, and to validate using the eligible NIR cohort
to sample controls in our main analysis, we used electronic pri-
mary care patient management system records to sample controls
from individuals enrolled at the same general practice as a case
and who had a non-cough related visit on the index date.
All data management and analyses were performed using SAS
version 9.4 (SAS Institute Inc., Cary, NC). Ethics permission was
granted from the NZ Health and Disability Ethics Committee.3. Results
There were 531,640 children born between 2006 and 2013
enrolled on the NIR. Of these, 11,457 (2%) had their immunisation
event details opted off the NIR, leaving 520,183 children eligible to
be included in the study.3.1. Vaccine coverage
Among eligible children, timely pertussis vaccination coverage
was highest for dose 1, with 87% percent of children receiving their
first dose of pertussis vaccine by age 8 weeks (Fig. 1). Seventy-six
percent received their third dose before 6 months of age. By their
first birthdays, 1% and 6% of children remained unvaccinated or
undervaccinated (received only 1–2 doses), respectively. Age
appropriate coverage for the primary series improved in more
recent birth cohorts - 66% of children born in 2006–2007 compared
to 86% of those born in 2012–2013 received their third dose prior
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Fig. 1. Pertussis vaccination coverage for doses 1–3 by age, New Zealand, 2006–
2013.
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their first booster dose before turning 5 years of age.3.2. Pertussis cases
From 2006 to 2013 there were 639 hospitalised pertussis cases
and 2831 non-hospitalised cases among eligible children less than
8 years of age. Twenty-five (1%) notified cases were excluded
because of missing NHI numbers. One (<1%) hospitalised case
and three (<1%) notified cases were excluded because their vacci-
nation records were inexplicable. Remaining in the analyses were
638 hospitalised and 2803 notified cases.
Across the study period the highest burden of both hospitalised
and non-hospitalised pertussis was in the youngest infants (Fig. 3).
Rates of pertussis hospitalisations for infants less than 6 months
old increased continuously from 2006 until they peaked at 546
per 100,000 person-years in 2012. Rates of non-hospitalised notifi-
cations in this age group rose slightly in 2009 followed by a second,
larger increase during the most recent epidemic, peaking in 2012
at 459 per 100,000 person-years. While non-hospitalised notifica-Fig. 2. Pertussis vaccination coverage for dose 3 by age and birth cohort, New
Zealand, 2006–2013.tion rates for thoseP6 months old also increased across the study
period, with the second highest rate at the 2012 peak in children
aged 2–3 years (394 per 100,000 person-years), hospitalisation
rates among these older infants and children remained relatively
constant.
Among hospitalised cases, the median age at hospitalisation
was 2 months (interquartile range [IQR]: 1, 6 months). Of the 625
(98%) children aged 6 weeks to 3 years, 576 (92%) had a primary
diagnosis of pertussis and 29 (5%) were admitted to the intensive
care unit (ICU). The median hospital stay was two days (IQR: 1,
5 days). Only 13 (2%) of the hospitalised cases were 4–7 years of
age. Compared to the younger hospitalised cases, fewer had a pri-
mary diagnosis of pertussis (n = 10 [77%]) and only 23% had a hos-
pital stay longer than one day. None were admitted to ICU. Non-
hospitalised cases were significantly older than hospitalised cases
(median 34 months [IQR: 16, 50 months], P < 0.001). Half
(n = 1402) of the non-hospitalised cases had laboratory confirma-
tion of pertussis.
Birthdates for controls ranged from 23 days before to 26 days
after case birthdates, with 93% of controls born within two days
of their matched case. Controls were significantly different from
cases with respect to ethnicity (hospitalised and non-
hospitalised) and socioeconomic status (hospitalised only) (all
P < 0.001) (Table 1). Cases and controls were similar for all other
measured characteristics.3.3. Vaccine effectiveness
Matched VE against pertussis hospitalisation following the first
dose was 43% (95% CI: 21, 58) among the youngest infants aged
6 weeks to 2 months (Table 2). VE increased significantly with each
dose in the primary series - 84% (95% CI: 72, 91) for dose 2 and 93%
(95% CI: 87, 96) for dose 3. This high level of effectiveness following
three doses (P91%) was maintained through to children’s fourth
birthdays. The number of cases was too small to calculate VE
against hospitalisation for older children.
Overall, VE for non-hospitalised notifications was lower than for
hospitalisations (Table 2). There was no measurable effectiveness
of one dose against pertussis notification in the youngest infants;
however, moderate protection was established following the sec-
ond dose (70%, 95% CI: 47, 83) with an additional, though non-
significant, increase following the third dose (87%, 95% CI: 82,
91). VE was stable as children aged to their fourth birthdays. Fol-
lowing the first booster dose there was again an additional, though
non-significant, increase in VE to 92% (95% CI: 89, 94) among 4-
year-olds, which was sustained in children aged 5–7 years (87%,
95% CI: 66, 95).
Adjusting for gender, ethnicity and socioeconomic status
resulted in reduced VE following the first dose, from 43% (95% CI:
21, 58) to 28% (95% CI: 0, 48) for hospitalised and from 28% (95%
CI: 23, 58) to 1% (95% CI: 73, 43) for non-hospitalised infants.
Confounding of these estimates was predominantly driven by dif-
ferences in ethnicity between the vaccinated and unvaccinated
groups. No confounding was observed for other age-dose combina-
tions, with fully adjusted estimates nearly identical to crude
matched estimates and no appreciable loss to precision. No sensi-
tivity analyses resulted in appreciably different VE estimates.4. Discussion
Pertussis resurgences around the world are a major challenge
for immunisation programmes. Populations using acellular pertus-
sis regimes are acknowledged to need a high coverage (>95%) pri-
mary course followed by one or more booster doses to prevent
clinical disease [1]. Most countries assume the need for a booster
Fig. 3. Incidence of hospitalised and notified pertussis, children born 2006–2013, New Zealand.
Table 1
Characteristics of pertussis cases and controls matched on age and residential region, children age 6 weeks to 3 years and born 2006–2013, by type, New Zealand.
Characteristic Hospitalisations Non-hospitalised notifications
Cases Controls P-value Cases Controls P-value
N (%) N (%) N (%) N (%)
Total N = 625 N = 12,428 N = 2028 N = 40,363
Age at pertussisa
6 w–2 m 322 (51.5) 6349 (51.1) 1.000 99 (4.9) 1972 (4.9) 1.000
3–4 m 122 (19.5) 2486 (20.0) 123 (6.1) 2479 (6.1)
5–11 m 104 (16.6) 2060 (16.6) 294 (14.5) 5871 (14.6)
1 y 36 (5.8) 717 (5.8) 545 (22.4) 9027 (22.4)
2 y 24 (3.8) 484 (3.9) 491 (24.2) 9790 (24.3)
3 y 17 (2.7) 332 (2.7) 567 (28.0) 11,224 (27.8)
Gender
Male 315 (50.4) 6343 (51.0) 0.756 1003 (49.5) 20,588 (51.0) 0.173
Female 310 (49.6) 6085 (49.0) 1025 (50.5) 19,775 (49.0)
Ethnicity
European 239 (38.2) 6232 (50.3) <0.001 1383 (68.4) 23,647 (58.8) <0.001
Ma¯ori 256 (41.0) 3207 (25.9) 418 (20.1) 8550 (21.3)
Pacific Islander 109 (17.4) 1370 (11.1) 128 (6.3) 3274 (8.1)
Asian 10 (1.6) 1382 (11.2) 65 (3.2) 3947 (9.8)
Otherb 11 (1.8) 196 (1.6) 28 (1.4) 808 (2.0)
NZ Deprivation Indexc
1–2 (least deprived) 45 (7.2) 1704 (13.8) <0.001 354 (17.5) 6749 (16.8) 0.134
3–4 60 (9.6) 1895 (15.3) 361 (17.9) 7296 (18.2)
5–6 77 (12.4) 2150 (17.4) 429 (21.2) 7889 (19.6)
7–8 152 (24.4) 2714 (21.9) 459 (22.7) 9115 (22.7)
9–10 (most deprived) 289 (46.4) 3924 (31.7) 417 (20.6) 9148 (22.8)
Region of residenced
Northern 225 (36.0) 4472 (36.0) 1.000 395 (19.5) 7862 (19.5) 1.000
Midland 131 (21.0) 2639 (21.2) 285 (14.1) 5693 (14.1)
Central 128 (20.5) 2524 (20.3) 552 (27.2) 10,985 (27.2)
Southern 139 (22.2) 2753 (22.2) 788 (38.9) 15,667 (38.3)
a Age at index date for controls.
b Other ethnicities not listed including Middle Eastern, Latin American and African.
c New Zealand Deprivation Index measures socioeconomic status. It is a relative measure of deprivation applied to small geographic areas and is based on nine questions
from the 2006 census [40].
d Regions defined by standard groupings of New Zealand’s 20 District Health Boards.
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employing a large study population for whom we could link data
from multiple sources, does not support that assumption.During an interval dominated by a prolonged pertussis epi-
demic we observed no reduction in VE between 6 months and
3 years of age following the 3-dose primary acellular pertussis vac-
Table 2
Estimated age and dose-specific vaccine effectiveness (VE) against hospitalised and notified pertussis, children born 2006–2013, New Zealand.
Age Doses Hospitalisations Non-hospitalised notifications
Cases Controls VE (95% CI) Cases Controls VE (95% CI)
N (%) N (%) Matcheda Adjustedb N (%) N (%) Matcheda Adjustedb
Total N = 638 N = 12,682 N = 2803 N = 55,662
6 w–2 m N = 322 N = 6329 N = 99 N = 1972
0 195 (60.6) 3420 (53.9) Ref Ref 45 (45.5) 804 (40.8) Ref Ref
1 127 (39.4) 2925 (46.1) 43 (21, 58) 28 (0, 48) 54 (54.4) 1166 (59.1) 28 (23, 58) 1 (73, 43)
3 m–4 m N = 122 N = 2486 N = 123 N = 2479
0 30 (24.6) 218 (8.8) Ref Ref 19 (15.5) 184 (7.4) Ref Ref
2 32 (26.3) 1165 (46.9) 84 (72, 91) 82 (68, 90) 48 (39.0) 1339 (54.0) 70 (47, 83) 68 (43, 82)
5 m–11 m N = 104 N = 2060 N = 294 N = 5871
0 36 (34.6) 97 (4.7) Ref Ref 66 (22.5) 240 (4.1) Ref Ref
3 39 (37.5) 1243 (60.3) 93 (87, 96) 93 (87, 96) 168 (57.1) 4451 (75.8) 87 (82, 91) 86 (80, 90)
1 y N = 36 N = 717 N = 454 N = 9027
0 15 (41.7) 32 (4.5) Ref Ref 124 (27.3) 372 (4.1) Ref Ref
3 18 (50.0) 642 (89.5) 94 (87, 97) 94 (86, 97) 315 (69.4) 8204 (90.9) 89 (86, 91) 89 (86, 91)
2 y N = 24 N = 484 N = 491 N = 9790
0 10 (41.7) 29 (6.0) Ref Ref 110 (22.4) 364 (3.7) Ref Ref
3 14 (58.3) 434 (89.7) 92 (79, 97) 91 (73, 97) 373 (76.0) 8980 (91.7) 86 (83, 89) 86 (83, 89)
3 y N = 17 N = 332 N = 567 N = 11,224
0 8 (47.1) 29 (6.0) Ref Ref 118 (20.8) 431 (3.8) Ref Ref
3 9 (52.9) 434 (89.7) 97 (90, 99) 98 (91, 99) 428 (75.5) 10,267 (91.5) 85 (82, 88) 84 (80, 88)
4 y N = 1 N = 19 N = 334 N = 6643
0 0 (0.0) 0 (0.0) Ref Ref 107 (32.0) 273 (4.1) Ref Ref
3 + 1 0 (0.0) 17 (89.5) – – 127 (38.0) 3840 (57.8) 92 (89, 94) 93 (90, 95)
5 y N = 7 N = 135 N = 253 N = 4979
0 2 (28.6) 3 (2.2) Ref Ref 85 (33.6) 211 (4.2) Ref Ref
3 + 1 5 (71.4) 114 (84.4) – – 139 (54.9) 4030 (80.9) 92 (88, 94) 93 (90, 95)
6 y N = 3 N = 60 N = 159 N = 3111
0 0 (0.0) 2 (3.3) Ref Ref 43 (27.0) 132 (4.2) Ref Ref
3 + 1 2 (66.7) 45 (75.0) – – 102 (64.2) 2494 (80.2) 87 (81, 91) 88 (82, 92)
7 y N = 2 N = 40 N = 29 N = 568
0 1 (50.0) 2 (5.0) Ref Ref 8 (27.6) 28 (4.9) Ref Ref
3 + 1 1 (50.0) 30 (75.0) – – 19 (65.5) 461 (81.2) 87 (66, 95) 91 (73, 97)
Notes: Age-specific VE estimates were not viable for hospitalisations among children 4–7 years of age due to small case numbers.
a Cases and controls were matched on age at pertussis index date and District Health Board area of residence.
b Matched model was adjusted by sex, ethnicity and socioeconomic deprivation index.
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ter dose at age 4 years. As expected, the VE estimates were high
against hospitalised, more severe pertussis [1] and lower against
non-hospitalised pertussis; however, the trajectories of the VE esti-
mates were similar for both severe and less severe pertussis out-
comes. Results from various sensitivity analyses did not change
our primary finding that there was no evidence of reducing VE fol-
lowing the primary 3-dose series through to age 3 years, or follow-
ing the first preschool-age booster dose through to age 7 years.
Our findings align with two recently published studies [8,10]
and two older studies [21,22], but conflict with a national-level
Australian study [9] and a meta-analysis [4]. The meta-analysis
suggested that the odds of pertussis increased by a multiple of
1.33 for every year since the last dose of acellular pertussis-
containing vaccine; however, the observed increase between inter-
vals of the time since last dose was not linear. Rather, the increase
was negligible 2–4 years after last dose and larger as time since last
dose grew to 6 years. Further, the meta-analysis was based on
studies with 3- and 5-dose schedules [30–34]. Results for 3-dose
schedules were not presented separately, making comparison to
our results challenging.
Our discordant findings with the national-level Australian study
likely depend on a number of factors. Australia has a history of sus-
tained high immunisation coverage and lower overall disease in
comparison to NZ where frequent exposure may lead to natural
boosting of wild and vaccine-derived immunity. Vaccination time-liness has also been historically better in Australia than in NZ. Dif-
ferences in disease surveillance practices may also play an
important role. Australia had high levels of PCR testing among per-
tussis notifications during the study period, ranging from nearly
60% in 2005 to over 90% in 2009 among children aged 1–4 years,
with even higher levels for infants aged under 1 year [35]. In our
study, a total of only 47% of notifications were PCR tested. Without
widespread testing, New Zealand’s notification criteria based on
clinical symptoms may under ascertain less overt pertussis cases.
The characterisation of pertussis strains in each country, given that
genetic adaptation of the pathogen and waning of vaccine-induced
immunity are inter-related [36–39], may also play a role in
explaining the discrepancies. While a single VE study documented
a high rate of pertactin deficiency among the small portion of iso-
lates that were tested [20], no VE studies to date have directly
incorporated relevant strain data. It has been documented in Aus-
tralia that increases in the prevalence of ptxP3 strains are associ-
ated with increased pertussis notification [40]. Additionally,
Australia has reported high frequency of B. pertussis isolates lack-
ing pertactin production [41]. Strain adaptations from NZ have not
been reported or published to date. A differential landscape of
genetic adaptations between the two settings could further explain
why an Australian study found significant waning immunity fol-
lowing a primary 3-dose schedule with no toddler booster.
A major strength of our study is NZ’s unique healthcare struc-
ture and linkable national data collections. We were able to deter-
182 S. Radke et al. / Vaccine 35 (2017) 177–183mine immunisation status for all but four of the total 3470 hospi-
talised and notified cases by linking directly to individuals’ NIR
records. We were also able to link hospital and notification data
so we could report on these outcomes separately. Results from sen-
sitivity analyses leant further weight to our findings.
Use of existing data meant we were restricted to covariable
information that was part of routine administrative and clinical
data collection. Though we were able to address more potential
confounders than previous studies, our results may still be subject
to unmeasured residual confounding. The structure of the NIR as a
birth cohort register is another potential limitation of our study
because it restricted the number of children who could be
observed in later childhood. In other words, during the 2006–
2013 observation period, all eight birth cohorts were observed dur-
ing their first year of life whereas only one birth cohort (infants
born in 2006) could be observed during their seventh year of life.
Together with the declining incidence of pertussis as children aged,
the constrained birth cohort structure of our study population
resulted in diminishing precision of the VE estimate for older age
groups. Still, the effect estimates for older age groups are steady
with heavily overlapping confidence intervals, meaning it is unli-
kely that there was any true but undetected decrease in VE as chil-
dren aged.
Adults and older siblings are the most important reservoir for
transmission of pertussis to infants and young children
[18,42,43]. Because whole-cell vaccine was discontinued only
6 years prior to the beginning of our study period, residual popula-
tion immunity among adolescents who received whole-cell vac-
cine in the 1990s may have provided indirect protection for
infants and children during our study period. Even though vaccina-
tion coverage in NZ was low in the 1990s – only 60–80% of children
received the full primary course of whole-cell pertussis vaccines
[27,44–46] – it is possible that retained protection from the
whole-cell vaccine era may have influenced our findings.
The incidence of pertussis increased across our study period;
however, this increase cannot be directly attributed to the removal
of the toddler booster dose in 2006. The static rates of hospitalisa-
tions we saw among older infants and toddlers suggests that
increased awareness during epidemics likely leads to increased
reporting of mild illness in these age groups. Also, both overall
and among toddlers, peak incidence during the 2011–2013 epi-
demic was similar to that observed in earlier epidemics during
1999–2000 and 2004–2005, prior to the 2006 removal of the acel-
lular toddler booster dose [41,47]. Importantly, the comparative
question of waning immunity cannot be addressed via absolute
measures of disease incidence. The consistency of our dose- speci-
fic VE measures across increasing age groups supports that
removal of the booster dose did not disproportionately affect dis-
ease incidence among toddlers.5. Conclusions
This study has shown sustained protection against both hospi-
talised and non-hospitalised presentations for pertussis through
to children’s fourth birthdays following a 3-dose primary course
of acellular pertussis-containing vaccine with no toddler dose.
After a booster dose at age 4 years VE was also sustained, with
no sign of waning over a further 3 years. Our investigation offers
diversity to previously studied settings, with an immunisation
schedule that starts earlier at age 6 weeks and a background of his-
torically low vaccine coverage and high burden of disease.
Our results suggest that a primary course alone sustains
vaccine-derived protection through to the fourth year of life, and
a booster dose at that time continues effective protection in thecontext of high circulating wild disease, particularly for the pre-
vention of more severe pertussis disease.
To consider whether genetic adaptation of the pertussis organ-
ism may be affecting the longevity of VE from acellular vaccines,
future studies should incorporate characterisation of pertussis
strains.
This study supports the NZ immunisation strategy of a primary
course starting at age 6 weeks and a booster dose in the fourth year
of life.Funding
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